Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (12964)	1/2/1998 4:25:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 32384

Off topic respond: NTII has Dynorphin A, a peptide analog of the human endorphins. Not from frog and very safe, already tested at a phase I study. No respiratory problems, no toxic problems. And it works. Problem it is a peptide, needs to be injected intravenously, other delivery sytem could be imagine: nasal, lungs, transcutaneous, oral with antienzymatic protection.... 2nd problem, the company has no money to comercially develop the drug. They are trying to sublicense it. 3rd problem, it is not easy, neither inexpensive to manufacture, case of many peptide compounds like insulin,epogen,bpi. NTII does not have this manufacturing ability. No wonder the stock price is approximately $1. If the frog drug is oral, they have an advantage. Morphine is very cheap, and very effective, but side effects are the problem. The frog drug is not addictive? being a nicotine receptor stimulant is a little difficult not to be, but biochemistry can bring surprises.